<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Immunotherapy for <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> aims to generate cytotoxic cells that are capable of eradicating <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>It has been well demonstrated that helper, non-cytotoxic CD4(+) T cells are important for the induction and maintenance of anti-<z:e sem="disease" ids="C1519680" disease_type="Disease or Syndrome" abbrv="">tumour immunity</z:e> exerted by cytotoxic CD8(+) T cells </plain></SENT>
<SENT sid="2" pm="."><plain>In contrast, the existence of direct anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e>, effector cytotoxic CD4(+) T cells remains elusive, mainly due to the paucity of reliable experimental data, especially in human B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphomas</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>This study developed an appropriate, autologous follicular B-cell non-Hodgkin follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> model, including the in vitro establishment of a malignant, human leucocyte antigen class I (HLA-I) deficient B-cell line, and the generation of three autologous anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cytotoxic CD4(+) T-cell clones originating from the peripheral blood of the same patient </plain></SENT>
<SENT sid="4" pm="."><plain>These three clones were considered as <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> specific, because they were capable of killing the malignant, HLA-I-deficient B-cell line through a classical HLA-II restricted perforin-mediated pathway, but did not lyse the Epstein-Barr virus-infected autologous <z:mpath ids='MPATH_458'>normal</z:mpath> B lymphocytes </plain></SENT>
<SENT sid="5" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three CD4(+)clones were T-cell receptor Vbeta17-Dbeta1-Jbeta1.2 and exhibited an identical complementarity-determining region 3, suggesting the immunodominance of a single <z:chebi fb="7" ids="16670">peptide</z:chebi> antigen presented by <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="6" pm="."><plain>Such <z:hpo ids='HP_0002665'>lymphoma</z:hpo> models would provide a useful tool for in vivo expansion and the adoptive transfer of selected CD4(+) cytotoxic cells in immunotherapeutic strategies </plain></SENT>
</text></document>